Subscribe

Sign In

Created For Sponsor

sponsored

Decoding Cancer: Multi-Omic AI Paving the Way for Personalized Treatment

Nexomic founders

By Newsweek Nexus

Share

Newsweek is a Trust Project member

Cancer is not one disease, and increasingly, neither is the way it is treated. Two patients may receive the same diagnosis yet have tumors with very different molecular characteristics—and those differences can influence whether a therapy works, how long it works, and how a cancer evolves under treatment.

The National Cancer Institute notes that even patients with the same cancer can have different genetic and molecular changes that affect treatment response.

That complexity is driving a new generation of precision-oncology approaches, including technology being developed by Nexomic, an AI TechBio company recognized as a winner of the 2026 Newsweek AI Impact Awards in the AI Healthcare: Best Outcomes and Diagnostics category.

Newsweek AI Impact Awards badge for winner Nexomic

Newsweek

At the heart of this work is DeepOmic, a tumor-agnostic multi-omic AI foundation model designed to learn complex cancer biology from patient molecular data. Rather than focusing on a single biomarker or narrowly defined prediction, the model integrates information across multiple molecular layers to identify patterns associated with treatment response, resistance, patient stratification, and biomarker discovery.

“As an oncologist, I have seen patients with the same cancer and the same treatment experience very different outcomes. That is what inspired Nexomic,” said Prof. Humaid O. Al-Shamsi, co-founder and chairman of Nexomic.

He continued: “Our goal is to use multi-omic AI to better understand who may benefit, why resistance develops, and how treatment can become more precise — while ultimately making this kind of biological intelligence more scalable, accessible and affordable for patients and health systems.”

That matters clinically because precision medicine is moving beyond the question of what cancer a patient has toward understanding the biology driving it. Biomarker testing helps identify patients who may benefit from targeted therapies and immunotherapies, and the FDA has approved multiple tumor-agnostic treatments based on molecular features rather than the cancer's origin.

For cancer patients, this multi-layered artificial intelligence technology translates into a deeply personalized approach to care by moving beyond one-size-fits-all treatments. Instead of evaluating a tumor through a single biomarker, DeepOmic maps multiple molecular layers to pinpoint precisely which therapies a patient's unique cancer biology will respond to, anticipate resistance before it happens, and steer individuals away from ineffective drugs toward interventions tailored specifically to their disease.

“What excites me about Nexomic is its ability to integrate multiple layers of tumor biology with clinical data and use AI to uncover patterns we might otherwise miss. From the perspective of a physician who is in clinic, the promise is straightforward: better matching the right treatment to the right patient and understanding why resistance eventually develops,” Chief of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Dr. Toni K. Choueiri, told Newsweek.

Choueiri is also a professor at Harvard Medical School and member of Nexomic’s Scientific Advisory Board.

Nexomic is seeking to extend that principle through its DECODE platform, applying DeepOmic to clinical-development data to investigate who responded, who did not, and why.

With more than 2.1 million new cancer cases and an estimated 626,140 cancer deaths projected in the U.S. in 2026 by the American Cancer Society, the need to turn sophisticated biological data into better treatment decisions is substantial.

For patients, the larger promise is more individualized decision-making—identifying treatments suited to their cancer while avoiding ineffective therapies.

A matched biomarker does not guarantee success, and cancer biology changes over time. Yet for Nexomic, the ultimate ambition is to move precision oncology another step forward: from explaining why a treatment worked after the fact toward understanding which patients will benefit before treatment begins.

sections

company

editions

contact

terms of use

sections

company

editions

contact

terms of use

© 2026 Newsweek Digital LLC